Latest news for Banco BPM (OTC:BNCZF) Stock

Banco BPM SpA is a financial services provider. It offers services including retail banking, corporate banking and private and investment banking/asset management.

BANCO BPM SOCIETA ORD by Banco BPM Societa Per Azioni

Banco BPM SpA

Barclays analyst Steve Valiquette maintains Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) with a Underweight and lowers the price target from $11 to $7.

News

Price Target

Analyst Ratings

Barclays Maintains Underweight on Walgreens Boots Alliance, Lowers Price Target to $7

–&nbsp; Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis&nbsp;–
GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4217125-1&amp;h=2601758121&amp;u=https%3A%2F%2Fprecigen.com%2F&amp;a=Precigen%2C+Inc.">Precigen, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4217125-1&amp;h=1226164084&amp;u=https%3A%2F%2Finvestors.precigen.com%2Fnews-releases%2Fnews-release-details%2Fprecigen-announces-groundbreaking-pivotal-study-data-prgn-2012&amp;a=PRGN-2012+AdenoVerse+gene+therapy+in+recurrent+respiratory+papillomatosis+(RRP)">PRGN-2012 AdenoVerse gene therapy in recurrent respiratory papillomatosis (RRP)</a>. Mr. Tennant will report to Precigen's President and CEO, Helen Sabzevari, PhD, and will join Precigen's executive leadership team.

Biotech

General

PGEN

Precigen To Spearhead First Potential Gene Therapy Launch

<ul>
<li>Approximately 40% of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp &nbsp;</li>
<li>Once-daily ZORYVE foam significantly improved both scalp and body psoriasis in a Phase 2b and a pivotal Phase 3 trial</li>
<li>Data also show rapid reduction in scalp itch as soon as 24 hours after first application</li>
<li>ZORYVE foam demonstrated a favorable safety and tolerability profile</li>
</ul>
WESTLAKE VILLAGE, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=1rc5uloepaLRUEBzCsDsd6-eN0q4k9US8wImyFHHqpkReNvF5mkw3Cm56x-Wdh0K-4fg8EujN_tYr7Hg4pQvB_xMv-EfX0A0sfNKG7Xw7_0=">Arcutis Biotherapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the submission of a supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) foam 0.3%, a once-daily, next generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis.

ARQT

Arcutis Submits Supplemental NDA For ZORYVE Foam To The FDA For The Treatment Of Scalp And Body Psoriasis In Adults And Adolescents Ages 12 And Over

Barclays analyst Jason Goldberg maintains Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) with a Equal-Weight and raises the price target from $43 to $47.

Barclays Maintains Equal-Weight on Truist Finl, Raises Price Target to $47

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is said to be planning to integrate its A18 chip into its upcoming entry-level iPhones and iPads in order to make them capable of running <a href="https://www.benzinga.com/topic/apple-intelligence">Apple Intelligence</a>, the company's suite of AI features.
What Happened: According to known <a href="https://weibo.com/5673255066/OoxQuAnxl?pagetype=profilefeed">tipster</a> Ice Universe, Cupertino is keen on extending its Apple Intelligence features to its entry-level devices. This news follows the speculations surrounding the specifications of the upcoming fourth-generation iPhone SE.
The tipster disclosed that the new iPhone SE would likely be powered by the A18 chip, the same chip anticipated to power the entire iPhone 16 lineup.
Traditionally, the iPhone SE has always utilized the chip from the latest iPhones. However, this year saw the introduction of Apple Intelligence, and <a href="https://www.benzinga.com/news/24/06/39267314/will-your-iphone-support-new-apple-intelligence-features-heres-what-you-need-to-know">only iPhones equipped with the A17 Pro chip</a> received the new AI features with iOS 18.
This could explain why all new iPhone 16 models will receive the A18 chip, to ensure access to the latest features.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Apple&#8217;s decision to use the A18 chip in the new iPhone SE suggests that the company is using AI features as a selling point. Rumors also suggest that the new HomePod with a touchscreen might be powered by the A18 chip, indicating that Apple may update the entry-level iPad and iPad mini with its latest chip.
See Also: <a href="https://www.benzinga.com/news/24/07/39835993/apple-denies-using-youtube-videos-to-train-its-ai-features-after-report-claims-tim-cooks-company-use">Apple Denies Using YouTube Videos To Train Its AI Features After Report Claims Tim Cook&#8217;s Company Used Creators&#8217; Content Without Consent</a>
Why It Matters: Apple&#8217;s AI-powered features, collectively known as <a href="https://www.benzinga.com/news/24/06/39256948/tim-cook-announces-apple-intelligence-for-iphones-calls-it-next-big-step-tremendously-excited">Apple Intelligence</a>, were first unveiled at the Worldwide Developers Conference in June.
Apple&#8217;s top executives clarified that the decision to limit Apple Intelligence features to the latest iPhone models was <a href="https://www.benzinga.com/news/24/06/39408910/limiting-apple-intelligence-features-not-a-tactic-to-boost-iphone-sales-say-top-executives-we-wouldv">not a tactic to boost iPhone sales</a>. If Apple does bring its AI feature set to entry-level iPhones, it would be the first time since the iPhone 14 that all the models run on the same chipset, instead of the entry-level models running a generation behind.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39881748/elon-musks-xai-flips-the-switch-on-100k-nvidia-h100-gpus-worth-up-to-4b-in-memphis-supercluster-most">Elon Musk&#8217;s xAI Flips The Switch On 100K Nvidia H100 GPUs Worth Up To $4B In Memphis Supercluster: &#8216;Most Powerful AI Training Cluster In The World&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Apple

Tech

AAPL

Apple Plans A18 Chip Integration To Bring AI Features To iPhone 16, Its Entry-Level Variants And iPads: Report

TransUnion Announces Partnership With SafeGuard Privacy To Streamline Marketers' Compliance Vetting For Third-Party Audience Vendors; Aims To Enhance First-Party Data Assets Amid Evolving Market

Peacock and its parent company, Comcast Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), are gearing up for a pivotal moment with the upcoming 2024 Olympics in Paris.
Pacock's president, Kelly Campbell, is spearheading efforts with two dedicated task forces to attract viewers during the Games and ensure they remain engaged afterward.
With the opening ceremonies just days away, Campbell and her superiors believe the Olympics will significantly boost Peacock's position in the competitive streaming landscape against giants like Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) and Walt Disney Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) Disney+, <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-07-22/comcast-bets-on-paris-olympics-to-make-peacock-a-must-have?srnd=phx-industries-entertainment&amp;sref=TBDibEcD" rel="noreferrer noopener">Bloomberg</a> reports.
"This is going to be a defining moment for Peacock," Campbell said in a recent interview. Over a 19-day period, Peacock will exclusively stream every Olympic event for U.S. viewers, offering thousands of hours of live and on-demand content, including a high-tech morning recap narrated by an AI-synthesized version of Al Michaels' voice.
For NBCUniversal, Comcast's media division, the stakes are high. The division, which owns several cable networks like Bravo, E!, and USA, faces significant pressure as viewers continue to shift from traditional TV bundles to streaming services, Bloomberg writes.
Comcast has invested billions into Peacock, yet it still trails behind competitors like Netflix and Walt Disney.
Comcast had intended to use the 2020 Tokyo Olympics to launch Peacock, but the pandemic delayed the launch. Despite the setbacks, the service launched in July 2020.
Related Read: <a target="_blank" href="https://www.benzinga.com/m-a/24/07/39838603/warner-bros-discovery-shares-are-surging-thursday-as-ceo-considers-asset-sales-spinoff" rel="noreferrer noopener">Warner Bros Discovery CEO Considers Asset Sales, Spinoff</a>
Unlike other streaming services, Peacock started as a free, ad-supported platform with optional paid tiers. Initially, it struggled to attract subscribers without the Olympic boost, but the pandemic created a captive audience that drove growth.
In a strategic meeting in 2021, Comcast CEO Brian Roberts approved increased investments in Peacock, including more original content, movies, and sports.
The platform has since reclaimed popular series and movies and released hit originals like "Poker Face" and "The Best Man: The Final Chapters." Peacock has also secured exclusive rights to major sports events, including NBA and NFL games, bolstering its appeal.
Peacock now costs $7.99 a month following price increases to fund new programming. Despite high churn rates, the service continues to attract new subscribers, partly due to its strategic releases during major sporting events.
The upcoming Olympics will feature promotions for new shows like "Fight Night" and "The Day of the Jackal," leveraging the excitement of the Games to retain viewers.
With 34 million subscribers as of March, Peacock outperforms some rivals in U.S. viewership.
Comcast stock has lost more than 5% in the last 12 months. Investors can gain exposure to the stock via&nbsp;IShares U.S. Telecommunications ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IYZ#BATS">IYZ</a>) and Vanguard Communication Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOX#NYSE">VOX</a>).
Price Action: CMCSA shares were trading lower by 3.04% at $38.93 premarket at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/06/39496372/comcasts-universal-plans-new-uk-theme-park-eyes-massive-job-creation-report" target="_blank" rel="noreferrer noopener">Comcast's Universal Plans New UK Theme Park, Eyes Massive Job Creation: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by rarrarorro on Shutterstock

CMCSA

iShares Dow Jones US Telecommunications Sector Index Fund

NFLX

Comcast's Paris Olympics Bet For Boosting Peacock's Viewership: Report

Ozuriftamab vedotin, the Company's conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in treatment-refractory patients with squamous cell carcinoma of the head and neck (SCCHN) in its Phase 2 clinical trial &nbsp;
The Company is on track to meet with the FDA for guidance on a potentially registrational trial in 2H 2024
SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ozuriftamab vedotin, the Company's conditionally and reversibly active ROR2 antibody drug conjugate directed for the treatment of patients with recurrent or metastatic SCCHN with disease progression on or after platinum-based chemotherapy and anti-PD-1/L1 antibody therapy.

BCAB

BioAtla Granted FDA Fast Track Designation For Ozuriftamab Vedotin For Treatment Of Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck

Market-Moving Exclusives

Exclusives

ADIL

EXCLUSIVE: Milestone Scientific Tells Benzinga 'This new price assignment applies to two Medicare regions: Jurisdiction L (JL) and Jurisdiction H (JH)'

Bionano Genomics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>), today announced&nbsp;the&nbsp;publication of&nbsp;the first&nbsp;multi-site study&nbsp;in multiple myeloma&nbsp;(MM)&nbsp;comparing&nbsp;optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural&nbsp;variants&nbsp;(SVs).
Multiple myeloma is a type of blood cancer originating in the plasma cell, known as a plasma cell neoplasm (PCN), and though sensitive and accurate identification of genetic abnormalities in MM samples is critical for patient risk stratification, predication of response to therapy options, and understanding of pathogenesis, many genome analysis methodologies, including fluorescence in situ hybridization (FISH) and chromosomal microarray (CMA), are limited in their ability to detect complex gene rearrangements in PCN samples. Additionally, karyotype (KT) fails for PCNs at a higher rate than for leukemias because plasma cells are fragile and grow poorly in culture, leaving additional unmet need. Because OGM doesn't require culture, it may be well suited to fill this gap.

BNGO

Bionano Announces Publication Of First Multi-Site Study To Analyze The Utility Of OGM In Multiple Myeloma

Barclays analyst Christine Cho maintains Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Equal-Weight and raises the price target from $16 to $19.

Barclays Maintains Equal-Weight on Sunrun, Raises Price Target to $19

MLSS

EXCLUSIVE: Milestone Scientific Tells Benzinga Co. Announces Medicare Price Assignment For The CompuFlo Epidural System In Texas, Pennsylvania, New Jersey, Colorado, Oklahoma, Louisiana, Arkansas, Mississippi, New Mexico, District Of Columbia, and Delawar

On Tuesday, Milestone Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#NYSE">MLSS</a>) announced that Novitas Solutions, Inc., a Jurisdictional Medicare Administrative Contractor (JMAC), has granted a Medicare Part B Physician payment rate for the company&#8217;s CompuFlo Epidural System under the American Medical Association&#8217;s (AMA) technology-specific Category III CPT code CPT0777T (real-time pressure-sensing epidural guidance system when used in conjunction with a primary ESI procedure).
This new price assignment applies to two Medicare regions:
<ul>
<li>Jurisdiction L (JL) includes Delaware, District of Columbia, Maryland, New Jersey, and Pennsylvania.</li>
<li>Jurisdiction H (JH) includes Arkansas, Colorado, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.</li>
</ul>
The pricing assignment by Novitas represents a significant step forward in Milestone Scientific&#8217;s strategy to ensure broad coverage and appropriate payment for the CompuFlo technology when deemed medically necessary and clinically appropriate for Medicare beneficiaries.
This decision follows the recently announced Medicare Jurisdiction N (JN) pricing assignment in Florida by First Coast Service Options Inc.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/07/39707524/exclusive-milestone-scientific-announces-favorable-medicare-pricing-for-compuflo-epidural-system-for" rel="noreferrer noopener">EXCLUSIVE: Milestone Scientific Announces Favorable Medicare Pricing For CompuFlo Epidural System For Back Pain Covering Florida</a>.
An estimated 3.0 million epidural steroid injection (ESI) procedures are performed yearly in these three jurisdictions (JL, JH, JN), representing approximately one-third of the total ESI procedures for treating chronic back pain in the United States.
Additionally, Medicare is expected to account for up to 40% of the clinical practice volume, representing an initial addressable market of approximately $250 million among Medicare patients in these three jurisdictions, the company said.
The CompuFlo Epidural System uses Milestone Scientific&#8217;s patented Dynamic Pressure Sensing technology, which provides real-time feedback to ensure accurate needle placement during epidural procedures. This technology is designed to reduce the morbidity, pain, and discomfort associated with traditional epidural techniques.
Price Action: MLSS stock is trading lower by 4.49% at $0.83 premarket at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39891711/anaptysbio-investigational-arthritis-drug-might-have-better-efficacy-profile-than-eli-lillys-anal" target="_blank" rel="noreferrer noopener">AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly&#8217;s: Analyst</a>.</li>
</ul>

Government

Health Care

EXCLUSIVE: Milestone Scientific Announces Medicare Price Assignment For CompuFlo Epidural System For Back Pain Covering Additional US States

With 7% interest rates or higher, housing markets across the country are still stagnant. But in certain markets around major east coast cities, buyers are snapping up homes. If you want to buy a home and can&#8217;t afford a property in the city, there&#8217;s still time to get into these markets before investors snap them up.&nbsp;
Don't Miss:
<ul>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>Will the surge continue or decline on real estate prices?<a href="https://www.benzinga.com/money/realbricks"> People are finding out about risk-free real estate investing that lets you cash out whenever you want.</a></li>
</ul>
Considering that the average <a href="https://www.zillow.com/home-values/44269/boston-ma/">home price in both Boston</a> and <a href="https://www.zillow.com/home-values/6181/new-york-ny/">NYC is over $750,000</a>, a home just two hours from a major city for $450,000 seems unbelievable. Unsurprisingly, according to a new report from Realtor.com, demand in the top 20 markets was 2.8 times the national level in June, as measured by views per property. America's hottest housing markets rose an average of 8.1% last year.
Hartford, CT, ranked as the country's hottest housing market this June, with an average home price of just $17,000 above <a href="https://fred.stlouisfed.org/series/MSPUS">the national average</a>. A home with a yard, a large kitchen, and multiple bedrooms and bathrooms in NYC could cost more than $1 million. In Hartford, only two hours from the city, you could get a comparable home for just $450,000.&nbsp;
In addition to Hartford, which came in at #1, Connecticut has four other cities in the top 20: New Haven-Milford, Worcester, Bridgeport-Stamford-Norwalk, and Norwich-New London.
Most other booming areas have one thing in common: proximity to major metropolitan areas with much better prices. Manchester, NH, coming in at #2, is just an hour from Boston. Its average home prices are higher than Hartford at $598,000, but still affordable compared to Boston. New Hampshire also has no state income or sales tax, giving both investors and residents more savings.&nbsp;
Trending: Rory McIlroy&#8217;s mansion in Florida is worth $22 million today, doubling from 2017 —<a href="https://benzinga.com/money/rory-mcilroys-florida-mansion-doubled-in-value"> here&#8217;s how to get started investing in real estate with just $100</a>
Rockford, IL, just 90 minutes outside Chicago, took the #3 spot with a median housing price of just $220,000. Rounding out the top five was Oshkosh-Neenah, WI, at #4, just 1.5 hours from Milwaukee or 40 minutes from Green Bay. Finally, Rochester, NY, in growing upstate NY, came in at #5. In Rochester, houses spend a median of 17 days on the market, 28 days less than the national average.&nbsp;
If you&#8217;re ready to buy, Benzinga can walk you through the <a href="https://www.benzinga.com/money/how-to-get-approved-for-a-mortgage">steps to get a mortgage</a>, or you can find the <a href="https://www.benzinga.com/money/best-mortgage-lenders">best online mortgage lenders</a>.
Here&#8217;s the full list of the top 20, with median list prices and average days on the market:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>City</td>
<td>Average List Price</td>
<td>Median Days on the Market</td>
</tr>
<tr>
<td>Hartford, CT</td>
<td>$450,000</td>
<td>17</td>
</tr>
<tr>
<td>Manchester, NH</td>
<td>$598,000</td>
<td>16</td>
</tr>
<tr>
<td>Rockford, IL</td>
<td>$220,000</td>
<td>19</td>
</tr>
<tr>
<td>Oshkosh, WI</td>
<td>$389,000</td>
<td>23</td>
</tr>
<tr>
<td>Rochester, NY</td>
<td>$300,000</td>
<td>17</td>
</tr>
<tr>
<td>Springfield, MA</td>
<td>$412,000</td>
<td>24</td>
</tr>
<tr>
<td>Akron, OH</td>
<td>$265,000</td>
<td>24</td>
</tr>
<tr>
<td>Guangzhou, OH</td>
<td>$255,000</td>
<td>22</td>
</tr>
<tr>
<td>Concord, NH</td>
<td>$600,000</td>
<td>26</td>
</tr>
<tr>
<td>Providence, RI</td>
<td>$599,000</td>
<td>23</td>
</tr>
<tr>
<td>Worcester, MA</td>
<td>$550,000</td>
<td>23</td>
</tr>
<tr>
<td>Bridgeport, CA</td>
<td>$960,000</td>
<td>25</td>
</tr>
<tr>
<td>Syracuse, NY</td>
<td>$350,000</td>
<td>28</td>
</tr>
<tr>
<td>Columbus, OH</td>
<td>$400,000</td>
<td>25</td>
</tr>
<tr>
<td>Reading, PA</td>
<td>$365,000</td>
<td>21</td>
</tr>
<tr>
<td>Erie, PA</td>
<td>$262,000</td>
<td>30</td>
</tr>
<tr>
<td>Lafayette, IN</td>
<td>$380,000</td>
<td>24</td>
</tr>
<tr>
<td>Norwich, CT</td>
<td>$550,000</td>
<td>30</td>
</tr>
<tr>
<td>Springfield, IL</td>
<td>$205,000</td>
<td>29</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
<li>Sun Belt's booming real estate market prepares for millions of new inhabitants —<a href="https://www.benzinga.com/money/integris"> Here&#8217;s how to find the region's best deals!</a></li>
</ul>

Real Estate

Exodus from NYC and Boston: How Connecticut's 'Bargain' $450K Homes Are Luring the Elite and Squeezing Out Locals

WIIM

ZIMV

ZimVie shares are trading higher after the company announced FDA clearance and U.S. launch of GenTek Restorative Components.

-- LB54640 has shown targeted effect on MC4R without hyperpigmentation&nbsp;-- &nbsp;
BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the first patients have been dosed in the Company's Phase 2 clinical trial evaluating LB54640, an investigational oral melanocortin-4 receptor (MC4R) agonist, in hypothalamic obesity.

RYTM

Rhythm Pharmaceuticals First Patients Dosed In Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 In Hypothalamic Obesity

Pending Stockholder Approval; Closing Expected On July 24, 2024

MOBX

Mobix Labs Announces Issuance And Sale Of 2.88M Shares Of Class A Common Stock And Warrants In $4M Private Placement; Series A And B Warrants Priced At $1.39 Per Share

Barclays analyst Christine Cho maintains Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) with a Overweight and lowers the price target from $18 to $12.

NOVA

Barclays Maintains Overweight on Sunnova Energy Intl, Lowers Price Target to $12

ZimVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>), a global life sciences leader in the dental market, today announced the U.S. launch of its GenTek&#xAE; Genuine Restorative Components product portfolio. The launch expands ZimVie's portfolio of end-to-end prosthetic offerings and follows the recent receipt of FDA 510(k) clearance. ZimVie first launched the GenTek portfolio in Europe in 2019 and has seen tremendous success in that market to date.

ZimVie Announces FDA Clearance And U.S. Launch Of GenTek Restorative Components

KNSA

Kiniksa Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY24 net product revenue guidance.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Banco BPM

News

Latest news for Banco BPM (OTC:BNCZF) Stock